

Table 2: Summary of Paclitaxel (Oral [oPac+E] and IV) Pharmacokinetic Parameters (PK Analysis Set, n=35)

Descriptive Statistics	Mean	SD	CV%	Min	Max	Median
Oral Paclitaxel (615 mg/m² over 3 consecutive days administered with encequidar)						
AUC_{0-t} (ng.h/mL)	4829.4	1375.1	28.5	3082.2	8685.3	4335.3
AUC_{0-∞} (ng.h/mL)	5033.5	1401.1	27.8	3289.8	8912.4	4512.8
C_{max} (ng/mL)	397.2	157.3	39.6	127.2	838.5	375.6
C_{max} (0-24h) (ng/mL)	366.4	156.8	42.8	113.4	838.5	375.6
C_{max} (24-48h) (ng/mL)	324.3	147.1	45.4	56.3	737.3	309.5
C_{max} (48-72h) (ng/mL)	296.1	127.2	43.0	93.6	559.2	294.2
T_{max} (0-24h) (h)	1.4	0.6	42.1	0.8	3.0	1.3
T_{max} (24-48h) (h)	25.4	1.1	4.3	24.0	30.5	25.1
T_{max} (48-72h) (h)	49.3	0.9	1.8	47.8	53.3	49.3
t_½ (h)	42.89	8.6	20.1	27.8	60.8	41.1
Intravenous Paclitaxel (80 mg/m²)						
AUC_{0-t} (ng.h/mL)	5431.8	1200.3	22.1	3502.3	8528.4	5265.1
AUC_{0-∞} (ng.h/mL)	5595.9	1264.1	22.6	3628.5	8969.6	5395.0
C_{max} (ng/mL)	2732.8	629.7	23.0	1720.3	4402.6	2543.0
T_{max} (h)	1.0	0.2	22.5	0.7	2.2	1.0
t_½ (h)	26.1	4.3	16.5	16.5	34.5	26.0

Note: The PK Analysis Set includes 35 subjects with complete PK profiles for both oral and IV paclitaxel.

IV = intravenous; Max = maximum; Min = minimum; PK = pharmacokinetic; SD = standard deviation